CD160-Enhanced Autologous T Cells for Advanced Biliary Tract Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, single-arm Phase 1 study evaluating the safety, tolerability, and early evidence of efficacy of BTC-Ag-T (ACH-AgT001) in adults with unresectable or metastatic biliary tract cancer that has progressed after gemcitabine-based therapy plus a PD-1/PD-L1 inhibitor. Participants receive BTC-Ag-T combined with cyclophosphamide and fludarabine as part of a lymphodepleting prep, followed by infusion of autologous antigen-specific T cells. Key outcomes include adverse events, leukapheresis feasibility, and preliminary tumor response per RECIST v1.1. The study is conducted at Shanghai Zhongshan Hospital, affiliated with Fudan University.

Why it matters

Who can join: the full rules

Major Inclusion Criteria:

Subjects must meet all of the following criteria to be enrolled:

1\. Age

\- Age ≥ 18 years at the time of signing informed consent. 2. Diagnosis

* Histologically or cytologically confirmed biliary tract malignancy (intrahepatic, perihilar, or distal extrahepatic cholangiocarcinoma, or gallbladder cancer).

  3\. Disease status
* Locally advanced unresectable or metastatic disease 4. Prior systemic therapy
* Patients (including those with refractory BTC and those with postoperative recurrence) must have received prior gemcitabine-based chemotherapy in combination with a PD-1/PD-L1 inhibitor.

  5\. Measurable disease
* At least one measurable lesion per RECIST v1.1 at baseline imaging.
* Sufficient viable tumor tissue from biopsy for antigen-presenting tumor cell (APTC) manufacturing 6. Adequate venous access and overall condition to tolerate leukapheresis. 7. Washout and lymphocyte recovery before leukapheresis 8. ECOG performance status 0 or 1 9. Organ function
* Hematology (no growth-factor support or transfusion within 5 days of testing, unless otherwise stated): ANC ≥ 1.0 × 10⁹/L; platelets ≥ 75 × 10⁹/L; hemoglobin ≥ 8.0 g/dL (transfusion to reach this threshold is permitted).
* Hepatic: total bilirubin ≤ 2.0 × ULN (≤ 3.0 × ULN allowed for documented Gilbert syndrome); AST and ALT ≤ 5.0 × ULN.
* Renal: serum creatinine ≤ 1.5 × ULN, or estimated creatinine clearance (e.g., Cockcroft-Gault) ≥ 40 mL/min.
* Adequate cardiopulmonary reserve to tolerate lymphodepleting conditioning and cell infusion in the investigator's judgment.

  10\. Viral serology
* No evidence of uncontrolled active viral infection.
* HIV-1/2 negative.
* Hepatitis B: HBV DNA is negative.
* Hepatitis C: HCV RNA is negative. 11. Contraception
* Women of childbearing potential and men whose partners are of childbearing potential must agree to use highly effective contraception from the time of informed consent through at least 12 months after BTC-Ag-T infusion (or longer if required by local regulation).

  12\. Pregnancy status
* Women of childbearing potential must have a negative serum or urine pregnancy test at screening.

  13\. Informed consent
* Able to understand and willing to sign a written informed consent document, and willing to comply with study procedures.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded:

1. Mixed/combined hepatocellular-cholangiocarcinoma, ampullary carcinoma, and other histologies not consistent with BTC
2. Prior allogeneic transplant or recent gene-modified cell therapy
3. Active CNS metastases
4. Patients with uncontrolled or high-risk active infection are excluded, including hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), and active tuberculosis (TB).
5. Active autoimmune disease requiring systemic immunosuppression
6. Significant cardiovascular disease
7. Significant pulmonary disease
8. Severe hepatic decompensation
9. Active variceal bleeding, or recent life-threatening portal-hypertension complications that cannot be stably controlled.
10. Another primary malignancy within the past 3 years, except: tumors treated with curative intent and at low risk of recurrence (e.g., adequately treated basal- or squamous-cell skin cancer, in-situ cervical cancer, or low-Gleason localized prostate cancer, occult thyroid carcinoma).
11. Severe hypersensitivity.
12. Pregnant or lactating women
13. Concurrent participation in another interventional study
14. Any other condition that, in the investigator's judgment, renders the patient unsuitable for enrollment.

Where it's running

• Shanghai Zhongshan Hospital, Fudan University
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Guoming Shi, MD, PhD — Department of Liver Surgery and Transplantation, Shanghai Zhongshan Hospital, Fudan University
• Study coordinator: Guoming Shi, MD, PhD
• Email: shi.guoming@zs-hospital.sh.cn
• Phone: +86 021-64041990

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Raman Spectroscopy to Diagnose Extrahepatic Cholangiocarcinoma

  This study is testing a new way to diagnose extrahepatic cholangiocarcinoma using a special light technique during a procedure to see if it can better identify cancer in the bile ducts.

  Recruiting University Hospital Olomouc · Olomouc, Olomouc Region · NCT06964425

• First-line combination therapy with adebrelimab, gemcitabine, and nab-paclitaxel for biliary tract cancers

  A multicenter, single-arm study tests whether a PD-1 blocker (adebrelimab) plus chemotherapy (gemcitabine and nab-paclitaxel) is safe and effective as first-line treatment for biliary tract cancers that can’t be surgically removed.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07668453

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• Identifying risk factors for gallbladder cancer and gallstone disease

  This study is trying to find out what causes gallbladder cancer and gallstone disease by looking at different lifestyle and genetic factors to help with early detection and prevention.

  Recruiting at 36 sites Centre Paul Strauss · Salta and 35 other locations · NCT06192719

• Liver transplantation for patients with advanced intrahepatic cholangiocarcinoma

  This study is testing if liver transplantation can help patients with advanced bile duct cancer live longer after they’ve had treatment, compared to those who only received chemotherapy.

  Recruiting at 2 sites Rutgers, The State University of New Jersey · Newark, New Jersey and 1 other locations · NCT06140134

• Comparing two methods of pain management during laparoscopic gallbladder surgery

  This study is testing whether a new pain management method that combines two techniques can help people feel less pain after gallbladder surgery compared to just one technique.

  Recruiting Helsinki University Central Hospital · Espoo, Uusimaa · NCT06123117

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.